



ASX ANNOUNCEMENT

Retirement of Dr Jason Loveridge as a Non-Executive Director

Sydney, 28 November 2018 - Actinogen Medical (ASX: ACW) wishes to advise that Dr Jason Loveridge has retired as a Non-Executive Director of Actinogen Medical, with effect from the conclusion of the AGM today, 28th November 2018.

Dr Loveridge was due for re-election at today's AGM, however due to work-related commitments in his executive role at the European-based 4SC, Dr Loveridge has made the decision that he was unable to stand again as a director of Actinogen Medical.

Dr Loveridge has been a Non-Executive Director of Actinogen Medical since the establishment of the company in 2014 and was temporarily Chairman in late 2016 and early 2017, prior to Dr Geoff Brooke's appointment.

Dr Loveridge was instrumental in initially identifying Xanamem as a potential licencing opportunity for Actinogen Medical, and he played a crucial role in the subsequent successful licencing negotiations with Edinburgh University in 2014.


Actinogen Medical thanks Dr Loveridge for his overall valued input, and his guidance of the Company from its founding to the position the company is now in, as it nears the read-out of the results in Q2 2019 from its landmark XanADu trial in Alzheimer's disease.

Dr Geoff Brooke, Chairman of Actinogen Medical, said "We sincerely thank Jason for the significant contribution he has made towards making the Company what it is today. We appreciate all of Jason's input; we hope for great success with his European endeavour, and we wish him and his family all the best for the future."

A decision on his replacement will be made by the Board in due course.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other

diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.